Interactive Features

Quiz

Quiz: Docetaxel Plus Radiotherapy For Cisplatin-Ineligible Patients With Head and Neck Carcinoma

09/02/2022

In a study evaluating the addition of docetaxel to radiotherapy for head and neck squamous cell carcinoma, which outcome was improved with docetaxel compared to radiation alone? Test your knowledge with our quiz.

In a study evaluating the...

09/02/2022

Oncology

Test Your Knowledge

Quiz: Single Agent Vs Combo Therapy for Cetuximab in CRC, Head and Neck Cancer

04/22/2021

True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.

True or False: Cetuximab, a...

04/22/2021

Oncology

Test Your Knowledge

Quiz: Is Lenvatinib a Second-Line Treatment Option for Patients with Thymic Carcinoma?

07/30/2020

True or False: Recent findings suggest that lenvatinib is a potential treatment option for patients with previously treated advanced or metastatic thymic carcinoma.

True or False: Recent findings...

07/30/2020

Oncology

Test Your Knowledge

Quiz: Is Age Tied to Disease Progression in Adults With Papillary Thyroid Cancer?

07/13/2020

Oncology

Test Your Knowledge

Quiz: Late-Line Bemarituzumab Therapy for Advanced Gastroesophageal Cancer

05/22/2020

True or False: Late-line bemarituzumab has been shown to be active and well-tolerated in patients with advanced FGFR2b-overexpressing gastric and GEA.

True or False: Late-line...

05/22/2020

Oncology

Test Your Knowledge

Quiz: Can Acupuncture Prevent Xerostomia in Head and Neck Cancer?

03/02/2020

True or False: Acupuncture may prevent radiation-induced xerostomia in patients with head and neck cancer.

True or False: Acupuncture may...

03/02/2020

Oncology

Test Your Knowledge

Quiz: Adding Which Drug to This Combo Therapy Improves Nasopharyngeal Carcinoma Outcomes?

11/08/2019

Adding which drug to cisplatin and chemoradiotherapy improved survival in patients with nasopharyngeal carcinoma?

Adding which drug to cisplatin...

11/08/2019

Oncology

Test Your Knowledge

Quiz: Temozolomide Combo for MGMT-Methylated Glioblastoma

10/01/2019

Which drug plus temozolomide is clinically beneficial for newly diagnosed MGMT-methylated glioblastoma?

Which drug plus temozolomide is...

10/01/2019

Oncology

Test Your Knowledge

Quiz: Palbociclib and Cetuximab as Therapy for HPV-Unrelated HNSCC

08/29/2019

True or False: Palbociclib and cetuximab therapy has shown promising activity in patients with HPV-unrelated, platinum- or cetuximab-resistant, head and neck squamous-cell carcinomas.

True or False: Palbociclib and...

08/29/2019

Oncology

Test Your Knowledge

Quiz: Risk for Brain Metastases Higher With Twice-Daily Radiotherapy for SCLC?

08/01/2019

True or false: Patients with SCLC undergoing radiotherapy twice daily are more likely to have brain metastases after prophylactic cranial irradiation than those given radiotherapy once daily.

True or false: Patients with...

08/01/2019

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology